Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer

Journal of Clinical Oncology

Volumn 15, Issue 9, 1997, Pages 3156-3163

  Hudes, Gary R ^a   Nathan, Faith ^a   Khater, Christina ^a   Haas, Naomi ^a   Cornfield, Mark ^a   Giantonio, Bruce ^a   Greenberg, Richard ^a   Gomella, Leonard ^a   Litwin, Samuel ^a   Ross, Eric ^a   Roethke, Susan ^a   McAleer, Cecilia ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMITOTIC AGENT; CHLORMETHINE; ESTRAMUSTINE; PACLITAXEL; PROSTATE SPECIFIC ANTIGEN; VINBLASTINE;

ADULT; AGED; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; HORMONAL THERAPY; HUMAN; MALE; METASTASIS; MICROTUBULE ASSEMBLY; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; STEADY STATE;

EID: 0030747033     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.9.3156     Document Type: Article

References (36)

1. Parker SL, Tong T, Bolden S, et al: Cancer statistics, 1996. CA Cancer J Clin 46:8-30, 1996
2. Eisenberger MA, Simon R, O'Dwyer PJ, et al: A re-evaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J Clin Oncol 3:827-841, 1985
3. Tew KD, Glusker JP, Hartley-Asp B, et al: Preclinical and clinical perspectives on the use of estramustine as an antimitotic drug. Pharmacol Ther 56:323-339, 1992
4. Dahllof B, Billstrom A, Cabrai F, et al: Estramustine depolymerizes microtubules by binding to tubulin. Cancer Res 53:4573-4581, 1993
5. Speicher LA, Laing N, Barone LR, et al: Interaction of an estramustine photoaffinity analogue with cytoskeletal proteins in prostate carcinoma cells. Mol Pharmacol 46:886-872, 1994
6. Stearns ME, Tew KD: Estramustine binds MAP-2 to inhibit microtubule assembly in vitro. J Cell Sci 89:331-341, 1988
7. Stearns ME, Wang M, Tew KD, et al: Estramustine binds a MAP-1-like protein to inhibit microtubule assembly in vitro and disrupt microtubule organization in DU-145 cells. J Cell Biol 107:2647-2656, 1988
8. Burns RG: Stoichiometry of estramustine phosphate binding to MAP2 measured by the disassembly of chick brain MAP2: Tubulin microtubules. Cell Motil Cytoskel 17:167-173, 1990
9. Wallin M, Deinum J, Friden B: Interaction of estramustine phosphate with microtubule-associated proteins. FEBS Lett 179:289-293, 1985
10. Amato RJ, Logothetis CJ, Dexeus FH, et al: Preliminary results of phase II trial of estramustine and vinblastine for patients with progressive hormone-refractory prostate carcinoma. Proc Am Soc Clin Oncol 7:207, 1988 (abstr)
11. Seidman A, Scher HI, Petrylak D, et al: Estramustine and vinblastine: Use of prostate specific antigen as a clinical trial end point for hormone-refractory prostate cancer. J Urol 147:931-934, 1992
12. Hudes GH, Greenberg R, Krigel R, et al: Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer. J Clin Oncol 10:1754-1761, 1992
13. Speicher LA, Barone L, Tew KD: Combined antimicrotubule activity of estramustine and taxol in human prostatic carcinoma cell lines. Cancer Res 52:4433-4440, 1992
14. Roth BJ, Yeap BY, Wilding G, et al: Taxol in advanced, hormone-refractory carcinoma of the prostate. A phase II trial of the Eastern Cooperative Oncology Group. Cancer 72:2457-2460, 1993
15. Hudes GR, Obasaju C, Chapman A, et al: Phase I study of paclitaxel and estramustine: preliminary activity in hormone-refractory prostate cancer. Semin Oncology 22:6-11, 1995 (suppl 6)
16. Wilson WH, Berg SL, Bryant G, et al: Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: A phase I/ II trial of 96-hour infusion. J Clin Oncol 12:1621-1629, 1994
17. Gunnarsson PO, Davidsson T, Andersson S-B, et al: Impairment of estramustine phosphate absorption by concurrent intake of milk and food. Eur J Clin Pharmacol 38:189-193, 1990
18. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
19. Yagoda A, Smith JA, Soloway MD, et al: Phase II study of estramustine phosphate in advanced hormone-refractory prostate cancer with increasing prostate specific antigen levels. J Urol 145:384A, 1991 (abstr)
20. Citrin DL, Wallemark C, Nadler R, et al: Estramustine effects bone mineral metabolism in metastatic prostate cancer. Cancer 58:2208-2213, 1986
21. Hartley-Asp B, Kruse E: Nuclear protein matrix as a target for estrmustine-induced cell death. Prostate 9:387-395, 1986
22. Pienta KJ, Lehr JE: Inhibition of prostate cancer growth by estramustine and etoposide: Evidence for interaction at the nuclear matrix. J Urol 149:1622-1625, 1993
23. Hussain MH, Pienta KJ, Redman BD, et al: Oral etoposide in the treatment of hormone-refractory prostate cancer. Cancer 74:100-106, 1994
24. Pienta KJ, Redman B, Hussain M, et al: Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. J Clin Oncol 12:2005-2012, 1994
25. Speicher LA, Barone LR, Chapman AE, et al: P-glycoprotein binding and modulation of the MDR phenotype by estramustine. J Natl Cancer Inst 86:688-694, 1994
26. Smith CD, Zilfou JT, Zhang X, et al: Modulation of p-glycoprotein activity by estramustine is limited by binding to plasma proteins. Cancer 75:2597-2604, 1995
27. Scher HI, Kelly WK: Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol 11:1566-1572, 1993
28. Kelly WK, Curley T, Leibertz C, et al: Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer. J Clin Oncol 13:2208-2213, 1995
29. Storlie JA, Buckner JC, Wiseman GA, et al: Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma. Cancer 76:96-100, 1995
30. IVa-tubulin isotypes in human prostate carcinoma cells as a result of estramustine resistance. Cancer Res 56:2584-2589, 1996
31. Colarusso PJ, Ranganathan S, Benetatos CA, et al: Altered tubulin isotype expression in a non-MDR mediated, paclitaxel-resistant human prostate carcinoma cell line. Proc Am Assoc Cancer Res 37:439, 1996 (abstr)
32. III cDNA. Proc Am Assoc Cancer Res 37:439, 1996 (abstr)
33. Laing NM, Dahloff B, Hartley-Asp B, et al: Interaction of estramustine with tubulin isotypes. Biochemistry 36:871-878, 1997
34. Panda D, Miller HP, Banerjee A, et al: Microtubule dynamics in vitro are regulated by the tubulin isotype composition. Proc Natl Acad Sci USA 91:11358-11362, 1994
35. Sella A, Kilbourn R, Amato R, et al: Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer. J Clin Oncol 12:683-688, 1994
36. Small EJ, Srinivas S, Egan B, et al: Doxorubicin and dose-escalated cyclophosphamide with granulocyte colony-stimulating factor for the treatment of hormone-resistant prostate cancer. J Clin Oncol 14:1617-1625, 1996